Multiple strategies are more efficient for cervical cancer

March 30, 2013
Multiple strategies are more efficient for cervical cancer
Multiple cervical cancer screening strategies that maximize early detection of high-grade disease without excessive increases in initial testing appear to be most effective, according to a study published in the March issue of the American Journal of Obstetrics & Gynecology.

(HealthDay)—Multiple cervical cancer screening strategies that maximize early detection of high-grade disease without excessive increases in initial testing appear to be most effective, according to a study published in the March issue of the American Journal of Obstetrics & Gynecology.

J. Thomas Cox, M.D., from the University of California in Santa Barbara, and colleagues compared nine screening strategies with the current standard (cytology plus human papillomavirus [HPV] triage of atypical squamous cells of undetermined significance) for detection of high-grade cervical disease in a cohort of 34,254 aged 30 years or older.

The researchers found that screening strategies with greater sensitivity necessitated more referral to colposcopy. For the detection of cervical intraepithelial neoplasia grade 2 or greater, HPV testing was more sensitive than cytology, but this sensitivity was decreased with strategies that depended on cytology for triage of HPV-positive women. Sensitivity was increased with various strategies of co-testing with cytology, but this was achieved by increasing testing. More efficient referral to colposcopy was provided by strategies that included integrated HPV16/18 testing.

"Strategies that maximize detection of women at greatest risk of cervical intraepithelial neoplasia grade 3 or greater by immediate referral to colposcopy, with follow-up testing of women at intermediate risk, maximize the benefits of cervical while decreasing the potential harm," the authors write. "Incorporating screening with HPV and triage of HPV-positive women by a combination of genotyping for HPV16/18 and provided a good balance between maximizing sensitivity (benefit) and specificity by limiting the number of colposcopies (potential harm)."

Several authors disclosed financial ties to the pharmaceutical and biotechnology industries, including Roche Molecular Systems, which funded the study.

Explore further: Cheaper and more effective test available for women following pre-cervical cancer treatment

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Cheaper and more effective test available for women following pre-cervical cancer treatment

November 1, 2012
Testing women to see if they are cured of HPV (the virus that can cause genital warts and cervical cancer) following treatment for abnormal cells on the surface of the cervix is more effective and cheaper than cytology testing ...

HPV testing in screening program saves 3,500 women from unnecessary tests

September 28, 2011
Testing for the human papillomavirus (HPV) as part of cervical screening reduces the number of women unnecessarily going on for further tests by over a third, new research shows today.

Recommended for you

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.